Cargando…
Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs
BACKGROUND: The resistance against antimalarial drugs represents a global challenge in the fight and control of malaria. The Brazilian biodiversity can be an important tool for research and development of new medicinal products. In this context, toxinology is a multidisciplinary approach on the deve...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centro de Estudos de Venenos e Animais Peçonhentos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812938/ https://www.ncbi.nlm.nih.gov/pubmed/33519927 http://dx.doi.org/10.1590/1678-9199-JVATITD-2020-0073 |
_version_ | 1783637755309326336 |
---|---|
author | Banfi, Felipe Finger Krombauer, Gabriela Camila da Fonseca, Amanda Luisa Nunes, Renata Rachide Andrade, Silmara Nunes de Rezende, Millena Alves Chaves, Mariana Helena Monção, Evaldo dos Santos Taranto, Alex Guterres Rodrigues, Domingos de Jesus Vieira, Gerardo Magela de Castro, Whocely Victor Varotti, Fernando de Pilla Sanchez, Bruno Antonio Marinho |
author_facet | Banfi, Felipe Finger Krombauer, Gabriela Camila da Fonseca, Amanda Luisa Nunes, Renata Rachide Andrade, Silmara Nunes de Rezende, Millena Alves Chaves, Mariana Helena Monção, Evaldo dos Santos Taranto, Alex Guterres Rodrigues, Domingos de Jesus Vieira, Gerardo Magela de Castro, Whocely Victor Varotti, Fernando de Pilla Sanchez, Bruno Antonio Marinho |
author_sort | Banfi, Felipe Finger |
collection | PubMed |
description | BACKGROUND: The resistance against antimalarial drugs represents a global challenge in the fight and control of malaria. The Brazilian biodiversity can be an important tool for research and development of new medicinal products. In this context, toxinology is a multidisciplinary approach on the development of new drugs, including the isolation, purification, and evaluation of the pharmacological activities of natural toxins. The present study aimed to evaluate the cytotoxicity, as well as the antimalarial activity in silico and in vitro of four compounds isolated from Rhinella marina venom as potential oral drug prototypes. METHODS: Four compounds were challenged against 35 target proteins from P. falciparum and screened to evaluate their physicochemical properties using docking assay in Brazilian Malaria Molecular Targets (BraMMT) software and in silico assay in OCTOPUS® software. The in vitro antimalarial activity of the compounds against the 3D7 Plasmodium falciparum clones were assessed using the SYBR Green I based assay (IC(50)). For the cytotoxic tests, the LD(50) was determined in human pulmonary fibroblast cell line using the [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay. RESULTS: All compounds presented a ligand-receptor interaction with ten Plasmodium falciparum-related protein targets, as well as antimalarial activity against chloroquine resistant strain (IC(50) = 3.44 μM to 19.11 μM). Three of them (dehydrobufotenine, marinobufagin, and bufalin) showed adequate conditions for oral drug prototypes, with satisfactory prediction of absorption, permeability, and absence of toxicity. In the cell viability assay, only dehydrobufotenin was selective for the parasite. CONCLUSIONS: Dehydrobufotenin revealed to be a potential oral drug prototype presenting adequate antimalarial activity and absence of cytotoxicity, therefore should be subjected to further studies. |
format | Online Article Text |
id | pubmed-7812938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Centro de Estudos de Venenos e Animais Peçonhentos |
record_format | MEDLINE/PubMed |
spelling | pubmed-78129382021-01-29 Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs Banfi, Felipe Finger Krombauer, Gabriela Camila da Fonseca, Amanda Luisa Nunes, Renata Rachide Andrade, Silmara Nunes de Rezende, Millena Alves Chaves, Mariana Helena Monção, Evaldo dos Santos Taranto, Alex Guterres Rodrigues, Domingos de Jesus Vieira, Gerardo Magela de Castro, Whocely Victor Varotti, Fernando de Pilla Sanchez, Bruno Antonio Marinho J Venom Anim Toxins Incl Trop Dis Research BACKGROUND: The resistance against antimalarial drugs represents a global challenge in the fight and control of malaria. The Brazilian biodiversity can be an important tool for research and development of new medicinal products. In this context, toxinology is a multidisciplinary approach on the development of new drugs, including the isolation, purification, and evaluation of the pharmacological activities of natural toxins. The present study aimed to evaluate the cytotoxicity, as well as the antimalarial activity in silico and in vitro of four compounds isolated from Rhinella marina venom as potential oral drug prototypes. METHODS: Four compounds were challenged against 35 target proteins from P. falciparum and screened to evaluate their physicochemical properties using docking assay in Brazilian Malaria Molecular Targets (BraMMT) software and in silico assay in OCTOPUS® software. The in vitro antimalarial activity of the compounds against the 3D7 Plasmodium falciparum clones were assessed using the SYBR Green I based assay (IC(50)). For the cytotoxic tests, the LD(50) was determined in human pulmonary fibroblast cell line using the [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay. RESULTS: All compounds presented a ligand-receptor interaction with ten Plasmodium falciparum-related protein targets, as well as antimalarial activity against chloroquine resistant strain (IC(50) = 3.44 μM to 19.11 μM). Three of them (dehydrobufotenine, marinobufagin, and bufalin) showed adequate conditions for oral drug prototypes, with satisfactory prediction of absorption, permeability, and absence of toxicity. In the cell viability assay, only dehydrobufotenin was selective for the parasite. CONCLUSIONS: Dehydrobufotenin revealed to be a potential oral drug prototype presenting adequate antimalarial activity and absence of cytotoxicity, therefore should be subjected to further studies. Centro de Estudos de Venenos e Animais Peçonhentos 2021-01-08 /pmc/articles/PMC7812938/ /pubmed/33519927 http://dx.doi.org/10.1590/1678-9199-JVATITD-2020-0073 Text en This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Banfi, Felipe Finger Krombauer, Gabriela Camila da Fonseca, Amanda Luisa Nunes, Renata Rachide Andrade, Silmara Nunes de Rezende, Millena Alves Chaves, Mariana Helena Monção, Evaldo dos Santos Taranto, Alex Guterres Rodrigues, Domingos de Jesus Vieira, Gerardo Magela de Castro, Whocely Victor Varotti, Fernando de Pilla Sanchez, Bruno Antonio Marinho Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs |
title | Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs |
title_full | Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs |
title_fullStr | Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs |
title_full_unstemmed | Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs |
title_short | Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs |
title_sort | dehydrobufotenin extracted from the amazonian toad rhinella marina (anura: bufonidae) as a prototype molecule for the development of antiplasmodial drugs |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812938/ https://www.ncbi.nlm.nih.gov/pubmed/33519927 http://dx.doi.org/10.1590/1678-9199-JVATITD-2020-0073 |
work_keys_str_mv | AT banfifelipefinger dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT krombauergabrielacamila dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT dafonsecaamandaluisa dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT nunesrenatarachide dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT andradesilmaranunes dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT derezendemillenaalves dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT chavesmarianahelena dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT moncaoevaldodossantos dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT tarantoalexguterres dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT rodriguesdomingosdejesus dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT vieiragerardomagela dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT decastrowhocelyvictor dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT varottifernandodepilla dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs AT sanchezbrunoantoniomarinho dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs |